# Trade Mark Journal No.2026/012 20 March 2026

## UK00004348561 3 March 2026 (5)

Mark 1

Mark 2

Mark 3

Mark 4

Class 5
  Pharmaceuticals; therapeutics; pharmaceuticals and therapeutics for the treatment of autoimmune diseases; pharmaceuticals and therapeutics for the treatment of inflammatory diseases and conditions; pharmaceuticals and therapeutics for the treatment of irritable bowel disease, metabolic disorders, psoriasis, psoriatic arthritis, hidradenitis suppurativa and ankylosing spondylitis.

Re-Aim Therapeutics Ltd

Representative: Kilburn & Strode LLP